Methods of treating cancer by targeting tumor-associated macrophages
US-2024415921-A1 · Dec 19, 2024 · US
US10183080B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10183080-B2 |
| Application number | US-201715694114-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 1, 2017 |
| Priority date | Sep 2, 2016 |
| Publication date | Jan 22, 2019 |
| Grant date | Jan 22, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Nanoparticles (and optionally a cargo such as a drug) can be delivered to cells by attaching just a single dendritic peptide to the nanoparticle. The dendritic peptide includes a polyhisitidine motif and a hinge and a spacer connecting the polyhistidine to a lysine-based dendritic wedge displaying at least two copies of a cell-penetrating peptide motif.
Opening claim text (preview).
What is claimed is: 1. A method of delivering a nanoparticle to a cell comprising: contacting a living cell with a nanoparticle bound to a single dendritic peptide thereby causing entry of the nanoparticle into the cell, wherein the dendritic peptide comprises a polyhisitidine motif and a hinge and a spacer connecting the polyhistidine to a lysine-based dendritic wedge displaying at least two copies of the peptide sequence RRRRRRRRRFG (SEQ ID No: 2). 2. The method of claim 1 , wherein the nanoparticle is also bound to a cargo which is delivered to the cell with the nanoparticle. 3. A method of delivering a nanoparticle to a cell comprising: contacting a living cell with a nanoparticle bound to a single dendritic peptide thereby causing entry of the nanoparticle into the cell, wherein the dendritic peptide comprises a hexahistidine motif connected to a lysine-based dendritic wedge displaying at least two copies of the peptide sequence RRRRRRRRRFG (SEQ ID No: 2) via a hinge and spacer comprising six prolines and two glycines. 4. The method of claim 3 , wherein the nanoparticle is also bound to a cargo which is delivered to the cell with the nanoparticle. 5. A method of delivering a nanoparticle to a cell comprising: contacting a living cell with a nanoparticle bound to a single dendritic peptide thereby causing entry of the nanoparticle into the cell wherein the dendritic peptide comprises a polyhisitidine motif and a hinge and a spacer connecting the polyhistidine to a lysine-based dendritic wedge displaying at least two copies of the peptide sequence RRRRRRRRRFG (SEQ ID No: 2); and wherein the nanoparticle is free of any other cell-penetrating peptides. 6. The method of claim 5 , wherein the nanoparticle is also bound to a cargo which is delivered to the cell with the nanoparticle.
Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title
Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT · CPC title
the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient · CPC title
the modifying agent being a protein, peptide or polyamino acid · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.